Skip to Content

Clinical Trials

Last Updated: 4/22/2014

Leukemia Clinical Trials are Grouped by Disease Type:

Phase I Agents

Acute Lymphoblastic Leukemia (ALL)

Newly Diagnosed or Previously Treated 

Salvage Programs

Acute Myelogenous Leukemia (AML)

Newly Diagnosed

    Newly Diagnosed FLT3 Mutated


    Unfit for induction chemotherapy

    Frontline AML Post-Hypomethylating Therapy for MDS

Secondary Leukemia


Supportive Care for AML

Maintenance (Patients in CR)

  • Oral AZA + BSC vs BSC as maintenance in AML in CR (2012-0866)
  • WT2725 Dosing Emulsion (2013-0404)

Myelodysplastic Syndrome (MDS) (Includes CMML)

Specific Situations

  • Hypoplastic MDS and aplastic anemia - Horse ATG (2012-0334)
  • MDS/MPN - Ruxolitinib + AZA (2012-0737)
  • FLT3Positive - Crenolanib (2012-0569)

RAS Mutated

Post Hypomethylating Agents:

Low Risk/IPSS Int-1

IPSS int-2 or high

Chronic Lymphocytic Leukemia (CLL)

CLL Immunotherapy

Untreated - early stage

Untreated - all stages 

Mimimal Residual Disease

Prior Therapy

Previously Treated with 17p Deletion

Supportive Care

Other Studies

Chronic Myelogenous Leukemia (CML)

Chronic phase

Accelerated Phase

Blastic Phase

Minimal Residual Disease

Treatment Discontinuation

  • Dasatinib Therapy Discontinuation (2013-0629)

Supportive Care

Other Studies

Roll-over Studies

Myeloproliferative Diseases


Supportive Care

Leukemia Insights

Leukemia Insights is a quarterly newsletter for physicians and other health professionals. Insights has the latest leukemia news, research and results from ongoing clinical trials, and available leukemia programs at MD Anderson.

© 2014 The University of Texas MD Anderson Cancer Center